The present invention relates to interleukin-1 converting enzyme inhibitors having the formula: ##STR1##

  • R is a carbocyclic or heterocyclic ring;
  • R1 is a cysteine trap;
  • R2a, R2a, R2b, and R2b are each independently hydrogen, C1-C4 alkyl, C1-C4 alkoxy, and mixtures thereof; or R2a and R2b can taken together to form a double bond;
  • L and L1 are linking groups having the formula: ##STR2##
  • T is selected from the group consisting of:
  • i) —NR6—;
  • ii) —O—;
  • iii) —NR6S(O)2—;
  • iv) —S(O)2NR6—; and
  • v) mixtures thereof;
  • R6 is hydrogen, substituted or unsubstituted C1-C20 linear, branched, or cyclic alkyl, C6-C20 aryl, C7-C20 alkylenearyl, and mixtures thereof; the indices w, w1, and w2 are each independently 0 or 1;
  • i) hydrogen;
  • ii) C1-C4 linear, branched, and cyclic alkyl;
  • iii) R3a and R3b or R4a, and R4b can be taken together to form a carbonyl unit;
  • iv) two R3a or two R3b units from adjacent carbon atoms or two R4a or two R4b units from adjacent carbon atoms can be taken together to form a double bond; and
  • v) mixtures thereof;

    the index m is from 0 to 5; the index n is from 0 to 5.

  •  
    Web www.patentalert.com

    < (R) and (S) isomers of substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxoisoindolines and methods of using the same

    < Indazole compounds useful as protein kinase inhibitors

    > Hepatitis C virus inhibitors

    > Galectin 11

    ~ 00259